91桃色

Smart nanocarriers; Inflammatory diseases; Drug delivery; Controlled release; Nanotechnology; Immune modulation; Personalized medicine

Introduction

Inflammatory diseases represent a diverse group of chronic conditions characterized by dysregulated immune responses and persistent inflammation, leading to tissue damage and dysfunction. Examples include rheumatoid arthritis, inflammatory bowel disease, psoriasis, and asthma, among others. These diseases impose substantial burdens on patients and healthcare systems worldwide, necessitating effective therapeutic strategies that can mitigate inflammation and restore tissue homeostasis. Traditional treatments for inflammatory diseases typically involve systemic administration of anti-inflammatory drugs, such as corticosteroids, nonsteroidal anti-inflammatory drugs (NSAIDs), or biologics. While these therapies can provide symptomatic relief and disease management, they often come with limitations, including systemic side effects, poor bioavailability at target sites, and the potential for long-term toxicity [1].

Nanotechnology has emerged as a transformative approach to address these challenges by offering precise control over drug delivery, targeting, and release kinetics. At the forefront of this innovation are smart nanocarriers—nanoscale drug delivery systems designed to respond to specific stimuli in the inflammatory microenvironment. These stimuli-responsive properties enable nanocarriers to release therapeutic agents locally at inflamed tissues, minimizing systemic exposure and enhancing therapeutic efficacy. The concept of smart nanocarriers revolves around their ability to exploit biological cues within inflamed tissues, such as pH gradients, enzymatic activity, or altered temperature, to trigger drug release. This targeted approach not only improves the delivery of anti-inflammatory agents but also reduces the risk of adverse effects associated with conventional therapies. Furthermore, smart nanocarriers can be engineered to deliver combinations of drugs or immunomodulatory agents, facilitating synergistic therapeutic effects and personalized treatment regimens [2-4].

This article explores the current landscape of smart nanocarriers for controlled release of therapeutics in inflammatory diseases. We discuss the design principles, mechanisms of action, and recent advancements in nanotechnology-driven approaches to combat inflammation. By elucidating these principles, we aim to highlight the transformative potential of smart nanocarriers in revolutionizing the treatment of inflammatory diseases and advancing personalized medicine. Smart nanocarriers represent a promising frontier in drug delivery for inflammatory diseases, offering targeted delivery, controlled release, and enhanced therapeutic outcomes. Their development holds the promise of optimizing treatment efficacy, minimizing side effects, and improving patient quality of life in the management of chronic inflammatory conditions [5].

Discussion

Design strategies of smart nanocarriers

Smart nanocarriers are designed with specific stimuli-responsive properties to achieve controlled drug release:

1. pH-responsive nanocarriers: These nanocarriers exploit pH gradients between inflamed tissues (typically acidic) and healthy tissues (neutral pH) to trigger drug release. pH-sensitive polymers or lipids undergo conformational changes in response to pH variations, facilitating controlled drug delivery.
2. Enzyme-responsive nanocarriers: Incorporation of enzyme-sensitive linkers or coatings allows nanocarriers to respond to elevated levels of specific enzymes (e.g., matrix metalloproteinases) present in inflamed tissues. Enzymatic cleavage triggers drug release, enhancing local therapeutic concentrations [6].
3. Temperature-responsive nanocarriers: Thermosensitive polymers undergo phase transitions in response to temperature changes within inflamed tissues, releasing drugs in a temperature-dependent manner. This approach ensures precise drug delivery while minimizing systemic exposure.

Targeting inflamed tissues

Smart nanocarriers can be functionalized with targeting ligands, such as antibodies or peptides, to enhance specificity for inflamed tissues. Surface modifications enable nanocarriers to selectively bind to receptors overexpressed on inflamed endothelial cells or immune cells, facilitating targeted drug delivery and minimizing off-target effects [7].

Modulating immune responses

In addition to delivering anti-inflammatory drugs, smart nanocarriers can modulate immune responses to restore immune homeostasis in inflammatory diseases:

1. Immunomodulatory agents: Nanocarriers can encapsulate immunomodulatory agents, such as cytokines, nucleic acids, or small molecules, to regulate immune cell activation and polarization within the inflammatory microenvironment.
2. Tolerogenic nanocarriers: Engineered nanocarriers can induce immune tolerance by delivering antigens in a controlled manner, promoting regulatory T cell responses and dampening inflammation [8].

Enhancing therapeutic outcomes

The precise control over drug release afforded by smart nanocarriers enhances therapeutic outcomes in inflammatory diseases:

1. Reduced side effects: Localized drug delivery minimizes systemic exposure, reducing systemic side effects associated with conventional therapies.
2. Improved patient compliance: Controlled release formulations can extend the duration of therapeutic action, reducing the frequency of administration and improving patient adherence to treatment regimens [9,10].

Clinical translation and challenges

Despite their promise, the clinical translation of smart nanocarriers faces challenges such as scalability, reproducibility, and regulatory approval. Standardization of manufacturing processes and rigorous preclinical and clinical evaluations are essential to ensure safety, efficacy, and commercial viability of smart nanocarriers for clinical applications.

Conclusion

Smart nanocarriers represent a transformative approach to delivering therapeutics in inflammatory diseases by enabling targeted, controlled release of drugs within the inflammatory microenvironment. By harnessing stimuli-responsive properties and targeting strategies, nanotechnology offers unprecedented opportunities to optimize drug efficacy, minimize side effects, and improve patient outcomes. Future research should focus on overcoming technical and regulatory challenges to accelerate the clinical translation of smart nanocarriers, advancing personalized medicine in the treatment of inflammatory diseases.

Acknowledgement

None

Conflict of Interest

None

References

1. Ampapon T, Wanapat M (2019)Tropical Animal Health and Production 51: 1489–1496.

, ,

2. Ramos-Morales E, De La Fuente G, Nash RJ, Braganca R, Duval S, et al. (2017)PLoS ONE 12: 1–14.

,

3. Bryszak M, Szumacher-Strabel M, El-Sherbiny M, Stochmal A, Oleszek W, et al. (2019)Journal of Dairy Science 102: 1257–1273.

, ,

4. Rodriguez S (2018)ProQuest Dissertations and Theses 85.
5. Flythe MD, Harlow BE (2019)Advances in Microbiology 09: 983–992.

,

6. Yausheva EV, Duskaev GK, Levakhin GI, Nurzhanov BS, Yuldashbaev YA, et al. (2019)IOP Conference Series: Earth and Environmental Science 341.

,

7. Zhou K, Bao Y, Zhao G (2019)Archives of Animal Nutrition 73: 30–43.

, ,

8. Díaz Carrasco JM, Cabral C, Redondo LM, Pin Viso ND, Colombatto D (2017) BioMed Research International.

,

9. Adelusi O, Isah O, Afolabi R, Aderinboye R, Idowu3 O, et al. (2016)Malaysian Journal of Animal Science 19: 19–30.
10. Avila A, Zambom MA, Faccenda A, Fischer ML, Anschau FA, et al. (2020)Animals 10: 1–12.

, ,